Werewolf Therapeutics, Inc. (HOWL) — Financial statements
Income statement, balance sheet, and cash flow for Werewolf Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00↓100.0% | 2↓90.5% | 20↑21.6% | 16 | 0.00 | |
| Cost of Revenue | 2↓9.9% | 2↑2.8% | 2↓29.7% | 3 | 0.00 | |
| Gross Profit | -2↓2401.4% | 0.07↓99.6% | 18↑30.9% | 14 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 45↓20.6% | 56↑35.1% | 42↓22.3% | 54↑52.4% | 35 | |
| General & Administrative Expenses | 16↓16.8% | 19↑2.0% | 19↑7.7% | 17↑16.9% | 15 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00↓100.0% | 4 | 0.00 | |
| SG&A Expenses | 16↓16.8% | 19↑2.0% | 19↓13.2% | 22↑45.1% | 15 | |
| Other Expenses | -2↑9.9% | -2↓2.8% | -2↑66.8% | -5 | 0.00 | |
| Operating Expenses | 59↓19.8% | 74↑25.5% | 59↓16.1% | 70↑39.7% | 50 | |
| Total Costs & Expenses | 61↓19.6% | 75↑24.9% | 60↓16.6% | 72↑44.7% | 50 | |
| Operating Results | ||||||
| Operating Income | -61↑17.6% | -74↓81.7% | -41↑27.7% | -56↓11.9% | -50 | |
| Depreciation & Amortization | 2↓9.9% | 2↑2.8% | 2↓29.7% | 3↑1062.0% | 0.22 | |
| EBITDA | -59↑7.8% | -64↓97.3% | -32↑36.7% | -51↓2.9% | -50 | |
| EBIT | -61↑7.9% | -66↓92.4% | -34↑36.4% | -54↓7.4% | -50 | |
| Interest & Other Income | ||||||
| Net Interest Income | -2↓207.4% | 2↓52.8% | 4↑124.2% | 2↑1734.6% | 0.10 | |
| Interest Income | 3↓53.4% | 7↓10.0% | 7↑288.7% | 2↑1734.6% | 0.10 | |
| Interest Expense | 5↑13.3% | 5↑48.3% | 3 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -8↓23.3% | -6↓179.3% | -2 | 0.00 | |
| Other Income / Expenses | -0.15↓104.7% | 3↓1.8% | 3↑39.6% | 2↑2059.6% | 0.10 | |
| Income Before Tax | -61↑13.7% | -71↓88.7% | -37↑30.6% | -54↓7.7% | -50 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -61↑13.7% | -71↓88.7% | -37↑30.6% | -54↓7.7% | -50 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -61↑13.7% | -71↓88.7% | -37↑30.6% | -54↓7.7% | -50 | |
| Bottom-Line Net Income | -61↑15.1% | -72↓91.7% | -37↑30.6% | -54↑73.4% | -202 | |
| EPS (Basic) | -1.32↑19.0% | -1.63↓55.2% | -1.05↑43.5% | -1.86↑83.0% | -10.94 | |
| EPS (Diluted) | -1.33↑18.4% | -1.63↓55.2% | -1.05↑43.5% | -1.86↑83.0% | -10.94 | |
| Weighted Average Shares | 46↑6.2% | 43↑21.6% | 36↑23.5% | 29↑56.4% | 18 | |
| Weighted Average Diluted Shares | 47↑6.7% | 44↑23.0% | 36↑23.5% | 29↑56.4% | 18 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.